LOS ANGELES, March 27 (Reuters) - An angina drug made by CV Therapeutics Inc. failed to prove effective as a treatment for acute coronary syndrome, but favorable safety data could broaden its use, ...

An angina drug called trimetazidine has been in the news lately connected to the 2022 Winter Olympics, but it's been on the radar of anti-doping authorities for years. Russian media reported that the ...

Palo Alto, California Fears over QT prolongation are mounting for a range of already approved drugs, as well as for agents still in the pipeline. This past week, ranolazine, CV Therapeutics' new ...

New York, NY - Fifteen US state attorneys general have signed a joint federal lawsuit against two pharmaceutical companies for allegedly delaying the entry of a competing hypertension/angina drug into ...